James D. Chambers, PhD, MPharm, MSc, professor of medicine at the Tufts Medical Center Institute for Clinical Research and Health Policy Studies, dives into why biosimilars contribute to a reduction ...

FDA approves an expanded access program that would offer patients an alternative to Merck’s bladder cancer medication.

In the third part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of ...

In the final part of her video interview with Pharma Commerce Editor Nicholas Saraceno, Laura Johnson, senior director of sales, life sciences, Loftware, comments on other concepts that are powering ...

Many would agree that over the past five years or so, telehealth has skyrocketed in popularity, as another way to provide clinical healthcare, increasing access to mental health and managed care. 1-4 ...

Leaders with top third-party logistics providers discuss the evolving landscape for the sector in 2025—and the new strides made in their quest to help transform the pharma supply chain. Third-party ...

The timing for the potential tax is yet to be determined, as the industry awaits to see the impact it could bring. The tariffs—if they do take effect—are expected to rise over the next year. The same ...

In the final part of his video interview with Pharma Commerce Editor Nicholas Saraceno, Jim Shehan, chair of the FDA regulatory practice at Lowenstein Sandler, explains how he anticipates the evolving ...

Click the title above for a link to open the Pharmaceutical Commerce February 2025 issue in an interactive PDF format.

In a video interview with Pharma Commerce, Laura Johnson, senior director of sales, life sciences, Loftware, discusses how supply chain collaboration is becoming increasingly important, particularly ...